BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer

SIMPLE SUMMARY: The combination of CDK4/6 inhibitors + fulvestrant or tamoxifen effectively prolongs survival in patients with estrogen receptor-positive (ER(+)) breast cancer. However, in the case of residual and metastatic disease, morbidity and mortality are virtually inevitable. Recently, the ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Elshazly, Ahmed M., Sinanian, Melanie M., Neely, Victoria, Chakraborty, Eesha, Alshehri, Muruj A., McGrath, Michael K., Harada, Hisashi, Schoenlein, Patricia V., Gewirtz, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452571/
https://www.ncbi.nlm.nih.gov/pubmed/37627092
http://dx.doi.org/10.3390/cancers15164066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452571/
https://www.ncbi.nlm.nih.gov/pubmed/37627092
http://dx.doi.org/10.3390/cancers15164066

Ejemplares similares